{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T16:56:02Z","timestamp":1791305762739,"version":"4.3.1"},"reference-count":28,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Acta Ophthalmologica"],"abstract":"Abstract<\/jats:title>\n \n Purpose<\/jats:title>\n To assess real\u2010world outcomes of intravitreal faricimab in French patients with neovascular age\u2010related macular degeneration (nAMD) previously treated with vascular endothelial growth factor (VEGF) inhibitors using data from the Fight Retinal Blindness! (FRB!) Registry.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n Retrospective analysis of prospectively collected FRB! Registry data (November 2023\u2013March 2026) on eyes switched to faricimab from other VEGF inhibitors. Primary endpoint: change in injection interval at 12\u2009months. Secondary endpoints: macular neovascularization (MNV) inactivation, visual acuity (VA), injections, switch\u2010off, safety. Mixed\u2010effects models assessed baseline predictors of interval change and loading\u2010dose effect on MNV inactivation.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n We included 222 eyes (169 patients; mean [SD] age 81.4 [7.8] years; VA 64.6 [19.3] letters; interval 5.9 [3.5] weeks; 26.2 prior injections); 143 (64.4%) were 12\u2010month completers. Mean interval increased from 6.0 to 8.4\u2009weeks (\n p<\/jats:italic>\n \u2009<\u20090.001), with a greater gain in inactive (\u0394 +4.0\u2009weeks) than active eyes (\u0394 +1.7\u2009weeks;\n p<\/jats:italic>\n \u2009=\u20090.033). VA remained stable (\u0394 \u22120.8 letters;\n p<\/jats:italic>\n \u2009=\u20090.28). Inactive MNV rose from 36% to 60% (\n p<\/jats:italic>\n \u2009<\u20090.001); 50% of active eyes achieved inactivation. After adjustment, MNV activity at switch was the only predictor of interval reduction (vs. inactive: SRFl only, \u03b2\u2009=\u2009\u22122.8\u2009weeks,\n p<\/jats:italic>\n \u2009=\u20090.015; IRF\/haemorrhage, \u03b2\u2009=\u2009\u22122.4\u2009weeks,\n p<\/jats:italic>\n \u2009=\u20090.020). A loading dose was not associated with interval extension (\n p<\/jats:italic>\n \u2009=\u20090.59) or MNV inactivation (\n p<\/jats:italic>\n \u2009=\u20090.50). Intraocular inflammation occurred in 5 eyes (2.3%).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n Macular neovascularization (MNV) inactivation and modest interval extension were observed in active eyes; inactive eyes showed a larger interval extension. Loading dose was not associated with better outcomes in this observational cohort. Safety was acceptable.<\/jats:p>\n <\/jats:sec>","DOI":"10.1111\/aos.70251","type":"journal-article","created":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T16:28:53Z","timestamp":1791304133000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Intravitreal faricimab in patients with\n nAMD<\/scp>\n : French data from the Fight Retinal Blindness! Registry"],"prefix":"10.1111","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8212-0705","authenticated-orcid":false,"given":"Eloi","family":"Debourdeau","sequence":"first","affiliation":[{"name":"Ophthalmology Department Gui de Chauliac Hospital Montpellier France"},{"name":"Montpellier University Montpellier France"},{"name":"Institute for Neurosciences of Montpellier INM, INSERM Montpellier France"},{"name":"The Save Sight Institute University of Sydney Sydney New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D\u00e9borah","family":"Harboun","sequence":"additional","affiliation":[{"name":"Ophthalmology Department Gui de Chauliac Hospital Montpellier France"},{"name":"Montpellier University Montpellier France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre\u2010Henry","family":"Gabrielle","sequence":"additional","affiliation":[{"name":"The Save Sight Institute University of Sydney Sydney New South Wales Australia"},{"name":"Department of Ophthalmology, Eye and Nutrition Research Group INRAe Universit\u00e9 Bourgogne Europe, CHU Dijon Bourgogne Dijon France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yohei","family":"Hashimoto","sequence":"additional","affiliation":[{"name":"The Save Sight Institute University of Sydney Sydney New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0501-1932","authenticated-orcid":false,"given":"Chloe","family":"Chamard","sequence":"additional","affiliation":[{"name":"Ophthalmology Department Gui de Chauliac Hospital Montpellier France"},{"name":"Montpellier University Montpellier France"},{"name":"Institute for Neurosciences of Montpellier INM, INSERM Montpellier France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederic","family":"Michon","sequence":"additional","affiliation":[{"name":"Ophthalmology Department Gui de Chauliac Hospital Montpellier France"},{"name":"Institute for Neurosciences of Montpellier INM, INSERM Montpellier France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4709-692X","authenticated-orcid":false,"given":"Benjamin","family":"Wolff","sequence":"additional","affiliation":[{"name":"The Save Sight Institute University of Sydney Sydney New South Wales Australia"},{"name":"Centre Ophtalmologique Maison Rouge Strasbourg France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9lo\u00efse","family":"Torres\u2010Villaros","sequence":"additional","affiliation":[{"name":"Ophthalmology Department Avicenne Hospital and Sorbonne Paris Nord University Bobigny France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"Giocanti\u2010Auregan","sequence":"additional","affiliation":[{"name":"Ophthalmology Department Avicenne Hospital and Sorbonne Paris Nord University Bobigny France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Gillies","sequence":"additional","affiliation":[{"name":"The Save Sight Institute University of Sydney Sydney New South Wales Australia"},{"name":"Discipline of Ophthalmology, Sydney Medical School The University of Sydney Sydney New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3587-4598","authenticated-orcid":false,"given":"Catherine","family":"Creuzot\u2013Garcher","sequence":"additional","affiliation":[{"name":"The Save Sight Institute University of Sydney Sydney New South Wales Australia"},{"name":"Department of Ophthalmology, Eye and Nutrition Research Group INRAe Universit\u00e9 Bourgogne Europe, CHU Dijon Bourgogne Dijon France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Daien","sequence":"additional","affiliation":[{"name":"Ophthalmology Department Gui de Chauliac Hospital Montpellier France"},{"name":"Montpellier University Montpellier France"},{"name":"Institute for Neurosciences of Montpellier INM, INSERM Montpellier France"},{"name":"The Save Sight Institute University of Sydney Sydney New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,10,6]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"crossref","DOI":"10.1186\/s40942-021-00307-7","article-title":"Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: a narrative review","volume":"7","author":"Anderson W.J.","year":"2021","journal-title":"International Journal of Retina and Vitreous"},{"key":"e_1_2_8_3_1","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ajo.2024.08.008","article-title":"Severe intraocular inflammation after intravitreal injection of faricimab: a single\u2010site case series of six patients","volume":"269","author":"Ben Ghezala I.","year":"2025","journal-title":"American Journal of Ophthalmology"},{"key":"e_1_2_8_4_1","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.oret.2024.01.004","article-title":"European unmet needs in the management of neovascular age\u2010related macular degeneration in daily practice","volume":"8","author":"Boudousq C.","year":"2024","journal-title":"Ophthalmology Retina"},{"key":"e_1_2_8_5_1","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1177\/11206721251374263","article-title":"Short\u2010term efficacy of faricimab switch on retinal exudative signs in patients requiring frequent anti\u2010VEGF injections: a real\u2010life study","volume":"36","author":"Charmasson M.","year":"2025","journal-title":"European Journal of Ophthalmology"},{"key":"e_1_2_8_6_1","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.oret.2022.03.024","article-title":"Predominantly persistent Intraretinal fluid in the comparison of age\u2010related macular degeneration treatments trials (CATT)","volume":"6","author":"Core J.","year":"2022","journal-title":"Ophthalmology Retina"},{"key":"e_1_2_8_7_1","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1001\/jamaophthalmol.2024.3828","article-title":"Sterile intraocular inflammation associated with Faricimab","volume":"142","author":"Cozzi M.","year":"2024","journal-title":"JAMA Ophthalmology"},{"key":"e_1_2_8_8_1","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ajo.2019.10.007","article-title":"Ten\u2010year treatment outcomes of Neovascular age\u2010related macular degeneration from two regions","volume":"210","author":"Gillies M.","year":"2020","journal-title":"American Journal of Ophthalmology"},{"key":"e_1_2_8_9_1","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1097\/IAE.0b013e318296b271","article-title":"Efficient capture of high\u2010quality data on outcomes of treatment for macular diseases: the fight retinal blindness! Project","volume":"34","author":"Gillies M.C.","year":"2014","journal-title":"Retina"},{"key":"e_1_2_8_10_1","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.oret.2025.03.015","article-title":"One\u2010year outcomes after switching to Faricimab in eyes with pretreated Neovascular age\u2010related macular degeneration: a Swiss retina research network report","volume":"9","author":"Grimaldi G.","year":"2025","journal-title":"Ophthalmology Retina"},{"key":"e_1_2_8_11_1","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/S0140-6736(22)00010-1","article-title":"Efficacy, durability, and safety of intravitreal faricimab up to every 16\u2009weeks for neovascular age\u2010related macular degeneration (TENAYA and LUCERNE): two randomised, double\u2010masked, phase 3, non\u2010inferiority trials","volume":"399","author":"Heier J.S.","year":"2022","journal-title":"The Lancet"},{"key":"e_1_2_8_12_1","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1136\/bjophthalmol-2014-305327","article-title":"Multi\u2010country real\u2010life experience of anti\u2010vascular endothelial growth factor therapy for wet age\u2010related macular degeneration","volume":"99","author":"Holz F.G.","year":"2015","journal-title":"The British Journal of Ophthalmology"},{"key":"e_1_2_8_13_1","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1111\/ceo.14589","article-title":"Outcomes after switching to Faricimab in Neovascular age\u2010related macular degeneration: data from the fight retinal blindness! Registry","volume":"53","author":"Hunt A.","year":"2025","journal-title":"Clinical & Experimental Ophthalmology"},{"key":"e_1_2_8_14_1","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1038\/s41433-025-03616-5","article-title":"1\u2010year real\u2010world outcomes of faricimab in previously treated neovascular age\u2010related macular degeneration","volume":"39","author":"Janmohamed I.K.","year":"2025","journal-title":"Eye"},{"key":"e_1_2_8_15_1","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s00417-023-06222-x","article-title":"Six\u2010month outcomes of switching from aflibercept to faricimab in refractory cases of neovascular age\u2010related macular degeneration","volume":"262","author":"Kataoka K.","year":"2024","journal-title":"Graefe's Archive for Clinical and Experimental Ophthalmology"},{"key":"e_1_2_8_16_1","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/j.ophtha.2024.02.014","article-title":"TENAYA and LUCERNE: two\u2010year results from the phase 3 neovascular age\u2010related macular degeneration trials of faricimab with treat\u2010and\u2010extend dosing in year 2","volume":"131","author":"Khanani A.M.","year":"2024","journal-title":"Ophthalmology"},{"key":"e_1_2_8_17_1","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1007\/s40123-025-01181-4","article-title":"Functional and anatomical outcomes of Faricimab in previously treated wet age\u2010related macular degeneration: systematic review and pooled analysis","volume":"14","author":"Khodor A.","year":"2025","journal-title":"Ophthalmology and therapy"},{"key":"e_1_2_8_18_1","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12155145","article-title":"Short\u2010term outcomes of Faricimab treatment in Aflibercept\u2010refractory eyes with Neovascular age\u2010related macular degeneration","volume":"12","author":"Kishi M.","year":"2023","journal-title":"Journal of Clinical Medicine"},{"key":"e_1_2_8_19_1","first-page":"e521","article-title":"The role of retinal fluid location in atrophy and fibrosis evolution of patients with neovascular age\u2010related macular degeneration long\u2010term treated in real world","volume":"100","author":"Llorente\u2010Gonz\u00e1lez S.","year":"2021","journal-title":"Acta Ophthalmologica"},{"key":"e_1_2_8_20_1","doi-asserted-by":"crossref","DOI":"10.3390\/life14040476","article-title":"Factors associated with success of switching to faricimab for neovascular age\u2010related macular degeneration refractory to Intravitreal Aflibercept","volume":"14","author":"Machida A.","year":"2024","journal-title":"Life"},{"key":"e_1_2_8_21_1","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/aos.16799","article-title":"Correlation of retinal fluid and photoreceptor and RPE loss in neovascular AMD by automated quantification, a real\u2010world FRB! Analysis","volume":"103","author":"Mares V.","year":"2024","journal-title":"Acta Ophthalmologica"},{"key":"e_1_2_8_22_1","doi-asserted-by":"crossref","DOI":"10.1186\/s12886-025-04463-4","article-title":"One\u2010year clinical outcomes of four\u2010dose induction versus immediate treat\u2010and\u2010extend faricimab regimens in pretreated neovascular age\u2010related macular degeneration","volume":"25","author":"Menghini M.","year":"2025","journal-title":"BMC Ophthalmology"},{"key":"e_1_2_8_23_1","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.oret.2023.12.001","article-title":"Rates of ocular adverse events after Intravitreal Faricimab injections","volume":"8","author":"Momenaei B.","year":"2024","journal-title":"Ophthalmology Retina"},{"key":"e_1_2_8_24_1","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1097\/IAE.0000000000004394","article-title":"Intraocular inflammation associated with faricimab therapy: one\u2010year real\u2010world outcomes","volume":"45","author":"Montesel A.","year":"2025","journal-title":"Retina"},{"key":"e_1_2_8_25_1","doi-asserted-by":"crossref","first-page":"e662","DOI":"10.1111\/aos.70134","article-title":"Predictive factors for injection interval extension after switching to faricimab in neovascular AMD: the FAR WEST multicentre study","volume":"104","author":"Posnic A.","year":"2026","journal-title":"Acta Ophthalmologica"},{"key":"e_1_2_8_26_1","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.jcjo.2023.10.017","article-title":"Long\u2010term effect of fluid volumes during the maintenance phase in neovascular age\u2010related macular degeneration in the real world: results from fight retinal blindness!","volume":"59","author":"Reiter G.","year":"2023","journal-title":"Canadian Journal of Ophthalmology. Journal Canadien d'Ophtalmologie"},{"key":"e_1_2_8_27_1","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ophtha.2013.08.011","article-title":"Intravitreal Aflibercept injection for neovascular age\u2010related macular degeneration","volume":"121","author":"Schmidt\u2010Erfurth U.","year":"2014","journal-title":"Ophthalmology"},{"key":"e_1_2_8_28_1","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.oret.2023.08.018","article-title":"Short\u2010term outcomes of faricimab in patients with neovascular age\u2010related macular degeneration on prior anti\u2010VEGF therapy","volume":"8","author":"Szigiato A.","year":"2024","journal-title":"Ophthalmology Retina"},{"key":"e_1_2_8_29_1","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-48190-6","article-title":"Therapeutic effects of faricimab on aflibercept\u2010refractory age\u2010related macular degeneration","volume":"13","author":"Tamiya R.","year":"2023","journal-title":"Scientific Reports"}],"container-title":["Acta Ophthalmologica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/aos.70251","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/aos.70251","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/aos.70251","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T16:28:57Z","timestamp":1791304137000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/aos.70251"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,6]]},"references-count":28,"alternative-id":["10.1111\/aos.70251"],"URL":"https:\/\/doi.org\/10.1111\/aos.70251","archive":["Portico"],"relation":{},"ISSN":["1755-375X","1755-3768"],"issn-type":[{"value":"1755-375X","type":"print"},{"value":"1755-3768","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,6]]},"assertion":[{"value":"2026-06-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-25","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-10-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"aos.70251"}}